Diabetes and ramadan: An update on use of glycemic therapies during fasting

Annals of Saudi Medicine

Volumn 31, Issue 4, 2011, Pages 402-406

  Ahmed, Mohamed H ^a   Abdu, Tarig A M ^b  

^a JAMES COOK UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF KHARTOUM   (Sudan)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; CHLORPROPAMIDE; EXENDIN 4; FRUCTOSAMINE; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCOSE; HEMOGLOBIN A1C; HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN LISPRO; INSULIN LISPRO MIX; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; LIRAGLUTIDE; METFORMIN; NEUTRAL PROTAMINE LISPRO; PIG INSULIN; REPAGLINIDE; SITAGLIPTIN; SULFONYLUREA; UNCLASSIFIED DRUG; VILDAGLIPTIN;

CLASSIFICATION ALGORITHM; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; DIABETES MELLITUS; DIET RESTRICTION; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG SAFETY; EVENING DOSAGE; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIPID METABOLISM; MEAL; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RAMADAN; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; RELIGION; REVIEW; RISK FACTOR; SIDE EFFECT; TREATMENT OUTCOME; WEIGHT GAIN;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FASTING; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN INFUSION SYSTEMS; ISLAM;

EID: 79961159873     PISSN: 02564947     EISSN: 09754466     Source Type: Journal    
DOI: 10.4103/0256-4947.81802     Document Type: Review

References (32)

1. Salti I, Benard E, Detournay B, Bianchi-Biscay M, Le BC, Voinet C, et al. A population-based study of diabetes and its characteristics during the fasting month of Ramadan in 13 countries: results of the epidemiology of diabetes and Ramadan 1422/2001 (EPIDIAR) study. Diabetes Care 2004;27:2306-11. (Pubitemid 39281377)
2. Shariatpanahi ZV, Shariatpanahi MV, Shahbazi S, Hossaini A, Abadi A. Effect of Ramadan fasting on some indices of insulin resistance and components of the metabolic syndrome in healthy male adults. Br J Nutr 2008;100:147-51.
3. Bouhlel E, Denguezli M, Zaouali M, Tabka Z, Shephard RJ. Ramadan fastings effect on plasma leptin, adiponectin concentrations, and body composition in trained young men. Int J Sport Nutr Ex-erc Metab 2008;18:617-27.
4. Haghdoost AA, Poorranjbar M. The interaction between physical activity and fasting on the serum lipid profile during Ramadan. Singapore Med J 2009;50:897-901.
5. Lamri-Senhadji MY, El KB, Belleville J, Bouchenak M. Assessment of dietary consumption and time-course of changes in serum lipids and lipoproteins before, during and after Rama dan in young Algerian adults. Singapore Med J 2009;50:288-94.
6. Aksungar FB, Eren A, Ure S, Teskin O, Ates G. Effects of intermittent fasting on serum lipid levels, coagulation status and plasma homocysteine levels. Ann Nutr Metab 2005;49:77-82. (Pubitemid 40827627)
7. Aksungar FB, Topkaya AE, Akyildiz M. Interleu-kin-6, C-reactive protein and biochemical parameters during prolonged intermittent fasting. Ann Nutr Metab 2007;51:88-95. (Pubitemid 46646621)
8. Khaled BM, Belbraouet S. Effect of Ramadan fasting on anthropometric parameters and food consumption in 276 type 2 diabetic obese women. Int J Diabetes Dev Ctries 2009;29:62-8.
9. Khaled BM, Belbraouet S. Ramadan fasting diet entailed a lipid metabolic disorder among type 2 diabetic obese women. Am J Appl Sci 2009;6:471-7.
10. Suliman M, Abdu T, Elhadd T, Ibrahim S, Ahmed MH, Malik R. Diabetes and fasting in Ramadan: Can we provide evidence-based advice to patients? Sudan Med J 2010;46(1):4-14.
11. Zargar AH, Siraj M, Jawa AA, Hasan M, Mahtab H. Maintenance of glycaemic control with the evening administration of a long acting sulphonylurea in male type 2 diabetic patients undertaking the Ramadan fast. Int J Clin Pract 2010;64:1090-4.
12. Schernthaner G, Grimaldi A, Di MU, Drze-woski J, Kempler P, Kvapil M, et al. GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients. Eur J Clin Invest 2004;34:535-42. (Pubitemid 39120222)
13. Al-Arouj M, Bouguerra R, Buse J, Hafez S, Hassanein M, Ibrahim MA, et al. Recommendations for management of diabetes during Ramadan. Diabetes Care 2005;28:2305-11. (Pubitemid 41242487)
14. Glimepiride in Ramadan (GLIRA) Study Group. The efficacy and safety of glimepiride in the management of type 2 diabetes in Muslim patients during Ramadan. Diabetes Care 2005;28:421-2.
15. Anwar A, Azmi KN, Hamidon BB, Khalid BA. An open label comparative study of glimepiride versus repaglinide in type 2 diabetes mellitus Muslim subjects during the month of Ramadan. Med J Malaysia 2006;61:28-35. (Pubitemid 43667242)
16. Sari R, Balci MK, Akbas SH, Avci B. The effects of diet, sulfonylurea, and Repaglinide therapy on clinical and metabolic parameters in type 2 diabetic patients during Ramadan. Endocr Res 2004;30:169-77. (Pubitemid 39243119)
17. Chia CW, Egan JM. Incretin-based therapies in type 2 diabetes mellitus. J Clin Endocrinol Metab 2008;93:3703-16.
18. Buse JB, Rosenstock J, Sesti G, Schmidt WE, Montanya E, Brett JH, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:39-47.
19. Garber A, Henry R, Ratner R, Garcia-Hernan-dez PA, Rodriguez-Pattzi H, Olvera-Alvarez I, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009;373:473-81.
20. Devendra D, Gohel B, Bravis V, Hui E, Salih S, Mehar S, et al. Vildagliptin therapy and hypogly-caemia in Muslim type 2 diabetes patients during Ramadan. Int J Clin Pract 2009;63:1446-50.
21. Bakiner O, Ertorer ME, Bozkirli E, Tutuncu NB, Demirag NG. Repaglinide plus single-dose insulin glargine: a safe regimen for low-risk type 2 diabetic patients who insist on fasting in Ramadan. Acta Diabetol 2009;46:63-5.
22. Cesur M, Corapcioglu D, Gursoy A, Gonen S, Ozduman M, Emral R, et al. A comparison of glyce-mic effects of glimepiride, repaglinide, and insulin glargine in type 2 diabetes mellitus during Ramadan fasting. Diabetes Res Clin Pract 2007;75:141-7. (Pubitemid 44894596)
23. Belkhadir J, el GH, Klocker N, Mikou A, Nasciri M, Sabri M. Muslims with non-insulin dependent diabetes fasting during Ramadan: treatment with glibenclamide. BMJ 1993;307:292-5. (Pubitemid 23220845)
24. Mafauzy M. Repaglinide versus glibenclamide treatment of Type 2 diabetes during Ramadan fasting. Diabetes Res Clin Pract 2002;58:45-53. (Pubitemid 34823624)
25. Mattoo V, Milicevic Z, Malone JK, Schwarzen-hofer M, Ekangaki A, Levitt LK, et al. A comparison of insulin lispro Mix25 and human insulin 30/70 in the treatment of type 2 diabetes during Ramadan. Diabetes Res Clin Pract 2003;59:137-43. (Pubitemid 36135832)
26. Mucha GT, Merkel S, Thomas W, Bantle J P. Fasting and insulin glargine in individuals with type 1 diabetes. Diabetes Care 2004;27:1209-10. (Pubitemid 38579794)
27. Kobeissy A, Zantout MS, Azar ST. Suggested insulin regimens for patients with type 1 diabetes mellitus who wish to fast during the month of Ramadan. Clin Ther 2008;30:1408-15.
28. Bin-Abbas BS. Insulin pump therapy during Ramadan fasting in type 1 diabetic adolescents. Ann Saudi Med 2008;28:305-6.
29. Azar ST, Khairallah WG, Merheb MT, Zantout MS, Fliti F. Insulin therapy during Ramadan fast for patients with type 1 diabetes mellitus. J Med Liban 2008;56:46. (Pubitemid 351427703)
30. Kassem HS, Zantout MS, Azar ST. Insulin therapy during Ramadan fast for Type 1 diabetes patients. J Endocrinol Invest 2005;28:802-5. (Pubitemid 43162834)
31. Kadiri A, Al-Nakhi A, El-Ghazali S, Jabbar A, Al AM, Akram J, et al. Treatment of type 1 diabetes with insulin lispro during Ramadan. Diabetes Metab 2001;27:482-6. (Pubitemid 32852457)
32. Reiter J, Wexler ID, Shehadeh N, Tzur A, Zan-gen D. Type 1 diabetes and prolonged fasting. Dia-bet Med 2007;24:436-9. (Pubitemid 46452400)